Bid Equity's XClinical acquires Carenity

XClinical announced separately that it has also acquired US-based Fortress Medical Systems.

The add-ons are supported by additional equity from Bid Equity II. The GP acquired a majority stake in Germany-based XClinical in September 2019 and announced that it intended to assist the company with the expansion of its product portfolio, as well as its international expansion, including via a buy-and-build strategy.

A source close to the situation told Unquote that XClinical is targeting profitable companies in the field of software for clinical trial processes, focusing on pre-clinical to phase-IV trials. The company will generally aim to acquire businesses with 15-150 employees, although it is not limited to this size range.

Company
Founded in 2011, Carenity is a social support platform for patients and care givers involved with clinical trials, with the aim of facilitating better communication between the two groups. The platform serves approximately 500,000 users across 1,000 chronic diseases. The company employs 25 staff and is headquartered in Paris.

People
Bid Equity – Helge Hofmeister, Axel Jansen, Lars Kloppsteck (managing partners).
XClinical – Franciscus Pijpers (CEO).
Carenity – Michael Chekroun (president, founder).

Advisers
Acquirer – Singular (commercial due diligence); Coffra (legal, tax); AC Christes (financial due diligence); TZ Consulting (technical due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• DACH
• Technology
• Acquisition finance
• Build-up
• Germany
• France